DemeRx, a Miami-based biopharmaceutical company founded by neuroscientist Deborah Mash, was the first organization to formally pursue FDA-regulated clinical trials of ibogaine and its primary metabolite noribogaine for opioid use disorder. Their Phase 1 safety trials in the early 2010s generated the first rigorous human pharmacology data on these compounds under a US Investigational New Drug (IND) application, laying groundwork that still shapes ibogaine research today.

Who Was DemeRx and What Did They Set Out to Do?

DemeRx was founded to translate decades of observational data — much of it collected by Deborah Mash herself at a licensed treatment facility in St. Kitts — into a formal FDA drug development program. The company filed IND applications for two distinct drug candidates:

  • Ibogaine hydrochloride (HCl) — the primary psychoactive alkaloid derived from the Tabernanthe iboga plant.
  • Noribogaine — ibogaine's main metabolite, which is longer-acting, less psychedelic, and was hypothesized to carry the sustained anti-addictive effects without as much hallucinogenic intensity.

The core therapeutic claim was that a single or small number of ibogaine doses could rapidly interrupt opioid physical dependence and reduce craving — a mechanism fundamentally different from maintenance therapies like methadone or buprenorphine. DemeRx aimed to position ibogaine as an acute detoxification and anti-craving agent, not a daily medication.

What Did the DemeRx Clinical Trials Actually Test?

DemeRx ran Phase 1 ascending-dose safety studies, the earliest required step in the FDA's drug approval pathway. These trials were not designed to prove efficacy — they were designed to characterize safety, pharmacokinetics, and the dose range tolerable in humans under controlled conditions.

The noribogaine Phase 1 trial, results of which were published by Glue et al. in the Journal of Clinical Pharmacology (2015), enrolled healthy volunteers and opioid-dependent subjects in New Zealand in collaboration with the University of Otago. Key findings included:

  • Noribogaine produced dose-dependent QTc interval prolongation — a cardiac electrical change that can, at sufficient magnitude, predispose to dangerous arrhythmias.
  • The compound demonstrated a very long half-life (approximately 28–49 hours), meaning cardiac monitoring would need to be extended well beyond dosing.
  • At lower doses, opioid withdrawal symptoms were measurably reduced in dependent participants.

A follow-up safety and tolerability study published in the American Journal of Drug and Alcohol Abuse (2016) provided three-month outcome data, showing the compound was tolerated but reinforcing cardiac monitoring requirements. The ibogaine HCl Phase 1 trial (NCT01290731) similarly focused on safety profiling in opioid-dependent adults.

Safety note: QTc prolongation is the central cardiac risk associated with both ibogaine and noribogaine. Multiple fatalities have been reported in uncontrolled settings worldwide, typically in individuals with undiagnosed cardiac conditions or concurrent substance use. All current clinical trials require pre-treatment cardiac screening, including ECG and echocardiography. This risk is a primary reason FDA approval has been complex and slow.

Why Did DemeRx's Program Stall?

DemeRx never advanced to Phase 2 efficacy trials under its own banner. Several factors converged to slow and ultimately suspend the program:

  • Cardiac liability: The QTc prolongation signal in noribogaine trials made regulators cautious. Designing a Phase 2 trial that adequately managed cardiac risk while still demonstrating efficacy required significant logistical and financial resources.
  • Funding constraints: Ibogaine development attracted limited venture capital interest through the 2010s, partly because Schedule I status in the US created legal complexity around manufacturing, handling, and investor appetite.
  • Regulatory pathway ambiguity: Without Breakthrough Therapy Designation or clear FDA guidance on an acceptable risk-management protocol, sponsors faced an uncertain development timeline.
  • Patent challenges: Competitive intellectual property questions arose around whether ibogaine analogs and formulations could be adequately protected given the compound's long prior-art history in research literature.

Deborah Mash continued publishing on ibogaine outcomes from the St. Kitts observational cohort — a 2018 paper in Frontiers in Pharmacology analyzed data from hundreds of patients — but a Phase 2 FDA trial did not materialize under the DemeRx structure.

What Has the Field Learned Since DemeRx?

DemeRx's IND-enabled trials created a scientific foundation that later researchers have built upon significantly. Several developments have accelerated the broader field:

  • Stanford/NIDA-funded research: A landmark study published in correspondence in Nature Medicine (2024) reported dramatic reductions in PTSD, depression, and disability scores among US Special Operations veterans treated with ibogaine in Mexico, where it is legal in licensed clinics. The data prompted bipartisan Congressional attention.
  • Magnesium pretreatment protocols: Research groups including those publishing preprints in 2024 have explored IV magnesium as a way to blunt QTc prolongation, potentially making cardiac risk more manageable in clinical settings.
  • ATAI Life Sciences and other sponsors: Multiple biotechnology companies currently hold active INDs or are pursuing IND applications for ibogaine-class compounds, including structural analogs designed to reduce cardiac liability.
  • Legislative momentum: The Veterans Expedited Recovery Act (VERA), introduced in the US Senate in 2024, proposed federal funding specifically for ibogaine research in veterans — signaling a shift in political feasibility.

Where Does the FDA Approval Race Stand Currently?

As of 2026, no ibogaine compound has reached Phase 3 trials or received FDA approval. The development landscape is more active than at any prior point, with several parallel tracks:

  • Mindstate Design Labs, Delix Therapeutics, and others are developing ibogaine analogs — sometimes called "ibogalogues" — engineered to reduce or eliminate the hallucinogenic and cardiac effects while preserving the neural plasticity signal believed responsible for therapeutic benefit.
  • Classic ibogaine clinical trials continue internationally, particularly in Canada, Australia, and Europe, generating efficacy data that may eventually support an FDA New Drug Application (NDA).
  • FDA Breakthrough Therapy Designation has not yet been publicly confirmed for any ibogaine compound, though it remains a strategic target for sponsors — designation can substantially shorten development timelines.

DemeRx's legacy is not a failed drug program so much as a proof of concept that ibogaine can be studied within the FDA framework. The IND pathway they opened, the pharmacokinetic data they generated, and the cardiac risk signals they quantified gave every subsequent researcher a more precise map of the terrain.

Is Ibogaine Legal in the United States?

Ibogaine is currently a Schedule I controlled substance under the Controlled Substances Act, meaning it is classified as having no accepted medical use and a high potential for abuse under federal law. Possession, manufacture, and distribution are illegal outside of FDA-authorized research. Some US veterans and patients travel to clinics in Mexico, Costa Rica, or other jurisdictions where ibogaine is legally administered. Researchers can study ibogaine under an approved IND, and Schedule I researcher registration through the DEA. No US state has independently rescheduled ibogaine, though legislative proposals have emerged in several states.

Frequently Asked Questions

Yes. Results from the noribogaine Phase 1 trials conducted in collaboration with the University of Otago were published by Glue et al. in the Journal of Clinical Pharmacology (2015) and the American Journal of Drug and Alcohol Abuse (2016). These remain among the most cited human pharmacology papers on noribogaine. DemeRx's ibogaine HCl trial (NCT01290731) findings were less comprehensively published in peer-reviewed form.
Noribogaine is the primary metabolite the human body produces when it breaks down ibogaine. It has a significantly longer half-life (roughly 28–49 hours versus ibogaine's 4–7 hours), is considerably less psychedelic, and has distinct receptor binding properties. DemeRx theorized that noribogaine's sustained presence in the body was responsible for the lasting anti-craving effects observed after ibogaine treatment, making it an attractive standalone drug candidate.
QTc interval prolongation is the primary cardiac concern. Both ibogaine and noribogaine prolong the QTc interval on ECG, which in susceptible individuals — particularly those with pre-existing cardiac conditions, electrolyte imbalances, or concurrent use of other QT-prolonging drugs — can progress to potentially fatal arrhythmias such as torsades de pointes. This is why cardiac screening before treatment and continuous monitoring during dosing are standard requirements in all current clinical research protocols.
As of 2026, no ibogaine compound has a publicly confirmed FDA Breakthrough Therapy Designation. Breakthrough Therapy status requires preliminary clinical evidence that the drug may offer substantial improvement over available therapies for a serious condition. Several sponsors are actively pursuing this designation, and the emerging efficacy data — particularly from veteran cohort studies — may strengthen those applications.
Deborah Mash is a neuroscientist and professor who has studied ibogaine since the early 1990s. She founded DemeRx and previously operated a licensed ibogaine treatment and research facility in St. Kitts, where she collected observational data on hundreds of patients over many years. Her 2018 Frontiers in Pharmacology paper on ibogaine detoxification outcomes is one of the largest published datasets on human ibogaine use. She is widely regarded as a central figure in the scientific effort to bring ibogaine through regulatory approval.
Yes, under specific legal conditions. A researcher must obtain a Schedule I researcher registration from the DEA and an approved Investigational New Drug (IND) application from the FDA before administering ibogaine to human subjects. Without both, administering ibogaine in the US is illegal regardless of intent. Several US academic institutions currently hold or are pursuing these authorizations.
Mexico, Costa Rica, the Netherlands, Portugal, South Africa, and several other countries permit ibogaine treatment in various legal frameworks, either because ibogaine is not scheduled or because licensed medical facilities can administer it under physician supervision. Canada has approved ibogaine access through its Special Access Program for certain patients. Legal status varies significantly by country and changes — always verify current regulations with local legal and medical professionals before making any decisions.

DemeRx's pioneering work demonstrated that ibogaine can be studied within the FDA's rigorous clinical framework — and that the path forward, while challenging, is navigable. If you are researching ibogaine for yourself or a loved one, please consult with an addiction medicine physician, a licensed mental health professional, and a legal expert familiar with your jurisdiction before making any decisions. The science is advancing rapidly, and qualified professionals can help you interpret current evidence in the context of your specific situation.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.